What medications can be prescribed for psoriasis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medications for Psoriasis

For mild psoriasis, prescribe topical corticosteroids (ultrahigh potency/class 1) combined with vitamin D analogues (calcipotriene/calcipotriol) as first-line therapy, while for moderate to severe psoriasis, biologics targeting IL-17 (ixekizumab, secukinumab, bimekizumab), IL-23 p19 (risankizumab, guselkumab), or infliximab should be considered first-line options based on their superior efficacy. 1, 2, 3

Topical Therapies (Mild Psoriasis)

First-Line Topical Options

  • Combination therapy is superior to monotherapy: Calcipotriene 0.005% plus betamethasone dipropionate 0.064% once or twice daily achieves 69-74% clear/almost clear status at 52 weeks versus 27% with vehicle 1
  • Class 1 ultrahigh potency topical corticosteroids are recommended with strength of recommendation A 1
  • Vitamin D analogues (calcipotriene, calcitriol, tacalcitol, maxacalcitol) for up to 52 weeks are recommended (strength A) 1
  • Calcipotriene foam or calcipotriene/betamethasone gel for scalp psoriasis (4-12 weeks, strength A) 1
  • Tacalcitol or calcipotriene with hydrocortisone for facial psoriasis (8 weeks, strength B) 1

Practical Topical Regimens

  • Weekday/weekend approach: Vitamin D analogues twice daily on weekdays + high-potency corticosteroids twice daily on weekends for maintenance (strength B) 1
  • Morning/evening split: High-potency corticosteroids in morning + vitamin D analogues in evening (strength B) 1

Critical Topical Pitfalls

  • Avoid salicylic acid with calcipotriene - the acidic pH inactivates calcipotriene 1
  • Apply vitamin D analogues AFTER phototherapy - UVA decreases calcipotriene concentration; thick calcipotriene layers block UVB 1

Systemic Therapies (Moderate to Severe Psoriasis)

Biologics (First-Line for Moderate-Severe Disease)

The most effective biologics are infliximab, bimekizumab, ixekizumab, and risankizumab, with similar clinical effectiveness when compared head-to-head 2. The AAD-NPF guidelines recommend biologics as first-line treatment for moderate to severe plaque psoriasis due to superior efficacy and acceptable safety profiles 3.

IL-17 Inhibitors

  • Ixekizumab, secukinumab, bimekizumab, brodalumab 3
  • Also approved for psoriatic arthritis 3

IL-23 p19 Inhibitors

  • Risankizumab, guselkumab, tildrakizumab, mirikizumab 3
  • Risankizumab and guselkumab now also approved for inflammatory bowel disease (Crohn's disease, ulcerative colitis) - making them preferred choices when IBD comorbidity exists 4

IL-12/23 p40 Inhibitor

  • Ustekinumab 3

TNF-α Inhibitors

  • Etanercept, adalimumab, certolizumab, infliximab 3
  • Also approved for psoriatic arthritis 3

Oral Small Molecules

Phosphodiesterase 4 Inhibitor

  • Apremilast - commonly prescribed in Japan (48.8% of plaque psoriasis patients) 5, 3

JAK Inhibitor (Off-Label)

  • Tofacitinib 5 mg twice daily or 10 mg twice daily (higher efficacy but increased adverse effects) 6
  • NOT FDA-approved for psoriasis but can be considered 6
  • Requires Shingrix vaccination before initiation 6
  • Do not initiate if: Lymphocytes <500/mm³, ANC <1000/mm³, hemoglobin <9 g/dL 6
  • Avoid with potent immunosuppressants (azathioprine, cyclosporine) or other biologics 6
  • Dose reduction to 5 mg once daily with moderate/severe renal or hepatic impairment 6

Traditional Oral Systemic Agents

Methotrexate

  • Traditional first-line oral agent 3
  • Can be combined with topical calcipotriene (strength A recommendation) 1

Acitretin (Vitamin A Derivative)

  • Most commonly prescribed for erythrodermic psoriasis (42.5%) and generalized pustular psoriasis (42.2%) in Japan 5
  • Can be combined with topical calcipotriene 1
  • CRITICAL CONTRAINDICATION: Women cannot consider pregnancy for 3 YEARS after discontinuation 6
  • Forms etretinate with concurrent alcohol ingestion 6
  • NOT a teratogen for male patients 6
  • Requires monthly LFTs and lipid profiles for first 3 months, then every 3 months 6

Cyclosporine

  • Can be combined with calcipotriene/betamethasone at low dose (2 mg/kg/day) for moderate-severe psoriasis (strength B) 1

Combination Strategies

Topicals + Biologics

  • Class 1 corticosteroid + etanercept for 12 weeks (strength A) 1
  • Calcipotriene/betamethasone + adalimumab for 16 weeks to accelerate clearance (strength B) 1
  • All topical corticosteroids can be combined with any biologic (strength C) 1

Phototherapy

  • Narrowband UV-B is the most commonly prescribed light therapy 3

Special Populations

Elderly Patients

Real-world data shows elderly patients more commonly receive phosphodiesterase 4 inhibitors or vitamin A derivatives as index treatment compared to younger patients 5

Psoriatic Arthritis

Biologics are more commonly selected for patients with psoriatic arthritis; specifically TNF-α inhibitors, IL-17 inhibitors, and p40IL-12/23 inhibitors are approved for this indication 5, 3

Latent Tuberculosis

The updated German guidelines extensively revised recommendations for interferon-gamma release assays, chest radiography indications, and suitability of systemic therapies in latent TB 4

Treatment Duration and Patterns

Real-world data demonstrates that over approximately 30 months, >85% of patients receive three or fewer lines of systemic therapy, and approximately 50% remain on at least one systemic drug throughout treatment 5. Biologics generally show longer time to discontinuation than oral medications 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.